8-K/A filed Nov 19, 2026 at 07:05 ET
CytoSorbents filed an 8-K/A amending its Q3 2026 earnings release to correct immaterial errors in foreign currency transaction losses, balance sheet amounts, and certain revenue percentages. The core financial results (revenue, gross profit, operating expenses, operating loss, and cash) are unchanged. The company reported Q3 2026 revenue of $9.7 million (+3% YoY), achieved operating cash flow breakeven of +$43,000 (excluding restructuring payments), and narrowed its adjusted EBITDA loss by 86% to $0.3 million. The company is advancing its DrugSorb-ATR De Novo submission to the FDA for early 2027.